Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed

Recruiting

18 years - 99 years

All

Phase 3

55 participants needed

1 Location

Brief description of study

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Pleural Mesothelioma,Mesothelioma
Age: 18 years - 99 years
Gender: All

Male and Female, Age 18 or older, pleural malignant mesothelioma

Updated on 04 Aug 2024. Study ID: 826355

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Brief description of study

Eligibility of study

Find a site

Interested in the study